AstraZeneca’s Truqap, Faslodex combo recommended for EU approval for breast cancer treatment
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) for approval within the European Union. This recommendation is intended for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer, specifically those with PIK3CA, AKT1, or […]
